Invention Grant
- Patent Title: Drug conjugates comprising antibodies against claudin 18.2
-
Application No.: US15565848Application Date: 2016-04-13
-
Publication No.: US11541127B2Publication Date: 2023-01-03
- Inventor: Ugur Sahin , Ozlem Tureci , Korden Walter , Maria Kreuzberg , Rita Mitnacht-Kraus , Fabrice Le Gall , Stefan Jacobs
- Applicant: Ganymed Pharmaceuticals GmbH , TRON—Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz GGMBH
- Applicant Address: DE Mainz; DE Mainz
- Assignee: Ganymed Pharmaceuticals GmbH,TRON—Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz GGMBH
- Current Assignee: Ganymed Pharmaceuticals GmbH,TRON—Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz GGMBH
- Current Assignee Address: DE Mainz; DE Mainz
- Agency: Neal, Gerber & Eisenberg LLP
- Agent Kevin A. O'Connor
- Priority: WOPCT/EP2015/058206 20150415
- International Application: PCT/EP2016/058056 WO 20160413
- International Announcement: WO2016/166122 WO 20161020
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K47/68 ; C07K16/30 ; C07K16/28 ; A61P35/04 ; A61P35/00 ; A61K31/40
Abstract:
The present invention provides anti-CLDN18.2 antibody-drug conjugates which are effective for treating and/or preventing cancer diseases associated with cells expressing CLDN18.2, including gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.
Public/Granted literature
- US20180117174A1 DRUG CONJUGATES COMPRISING ANTIBODIES AGAINST CLAUDIN 18.2 Public/Granted day:2018-05-03
Information query
